Trial Profile
A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Elasomeran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms COVE Transplant
- Sponsors Moderna Therapeutics
- 08 Sep 2023 Status changed from active, no longer recruiting to completed.
- 31 Aug 2022 Planned primary completion date changed from 31 May 2023 to 31 Jan 2024.
- 31 Aug 2022 Status changed from recruiting to active, no longer recruiting.